Allianz Director John Schroer discusses the recent pullback in biotech and the opportunities for turnarounds.» Read More
The rally on Wall Street fizzled Monday, snapping a four-day streak that sent stocks up more than 4 percent. The Dow ended pretty much flat, while the Nasdaq and S&P 500 shed 0.1 percent.
Dividend yields in the Dow index are down about a quarter of a point since early June and 165 basis points since early March, as equity markets continue to trend higher, pushing yields lower. Here is a look at the dividend yields of all 30 Dow components:
The Dow jumped 150 points off the morning lows. Does this bullish reversal mean you should jump back in?
Stocks got a weak start after the selloff in China but rebounded by midday after a report showed a surprise drop in crude inventories, which sent oil prices — and energy stocks — soaring.
Compared to an average short interest of 2.2% for all Dow components, bets against these three companies stand at around 8%.
Cramer makes the call on viewers' favorite stocks.
The correction may finally be starting: Stocks plunged more than 2% Monday in their worst selloff in 7 weeks. The Nasdaq was the hardest hit, down nearly 3%.
Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.
OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.
Some people may not expect Regis Philbin to be an investor type, but he’s been actively trading since 1983.
Barry James, president of the James Advantage Funds and Hugh Johnson, chairman and CIO of Johnson Illington Advisors discussed their economic outlooks and shared their investment strategies.
Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.
A sigh of relief can be heard by all after two brutal years in the equity markets. But there is something interesting occurring that is gaining little attention. Companies with consistent, stable cash flow, (and not highly leveraged) are underperforming more risky leveraged assets. What's going on?
Daniel Loeb's Third Point fund, with $1.8 billion in assets under management, has had a successful second quarter. In its most recent letter to investors, acquired by CNBC, the hedge fund reports the following returns and holdings.
In sports, it’s important to play defense AND offense. In investing, the same holds true. After months of defensive strategies, consider your overall offensive strategy as we seem to be seeing an apparent turn in the world's economic fortunes.
Following are the week’s biggest winners and losers. Find out why shares of Nike and American Superconductor popped while Exxon Mobil and Pfizer dropped.
As the markets continue to surge ahead, the equities on the Nasdaq and New York Stock Exchange continue to hit new highs. 61 companies on the NYSE and a whopping 116 companies on the Nasdaq hit new 52-week highs yesterday.
Dividend yields in the S&P 500 are down since late June, as a 6% rally for the US equity index this month has pushed yields lower, and companies remain cautious about increasing their dividend payouts.
Apparently, Nancy Reagan isn't the only one saying no to drugs. Options Traders appear to be living in an 80s PSA as well, shunning shares of Pfizer through some heavy put buying.
Shares of Acadia Pharmaceuticals skyrocketed along with heavy options activity at the end of last week.